Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2857–2880 of 26,684 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Multiple Sclerosis
Interventions: Laquinimod, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 2,199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 32
States / cities: Cullman, Alabama • Sun City, Arizona • Tucson, Arizona + 29 more

Conditions: Frontotemporal Dementia
Interventions: Part 1 Blinded - AL001, Part 1 Blinded - Placebo, Part 2 (OLE Treatment) - AL001, Part 2 (OLE Treatment) - Placebo Switched to AL001; Drug
Lead sponsor: Alector Inc.; Industry
Eligibility: 25 Years to 85 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 14
States / cities: Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 11 more

Conditions: Pregnancy, Pain
Interventions: Group #1: VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure, Group #2: Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure, Group #3: Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure; Device · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Alcoholism
Interventions: acamprosate; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Huntington Disease
Interventions: SKY-0515, SKY-0515 Placebo; Drug
Lead sponsor: Skyhawk Therapeutics, Inc.; Industry
Eligibility: 25 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Englewood, Colorado • Boston, Massachusetts • Charlestown, Massachusetts + 1 more

Conditions: Resistant Hypertension
Interventions: XXB750 drug, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 18
States / cities: Anniston, Alabama • Birmingham, Alabama • Sacramento, California + 15 more

Conditions: Osteoarthritis, Pain
Interventions: Placebo, Fulranumab 1 mg, Fulranumab 3 mg, Celecoxib 100 mg, Celecoxib 100 mg Matching Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 32
States / cities: Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 29 more

Conditions: Cystic Fibrosis
Interventions: azithromycin 250 mg tablets, placebo tablets; Drug
Lead sponsor: CF Therapeutics Development Network Coordinating Center; Network
Eligibility: 6 Years to 18 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 31
States / cities: Phoenix, Arizona • Hartford, Connecticut • Atlanta, Georgia + 27 more

Conditions: Milk and/or Peanut Allergy
Interventions: Peanut powder and Oat flour, Peanut flour and Oat flour (placebo for peanut flour), Dry Milk Powder and Corn Starch (placebo for Milk powder), Baked milk and Rice milk (placebo for Baked milk); Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 21 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: Endotracheal tube insertion, Laryngeal mask airway insertion; Device
Lead sponsor: Albany Medical College; Other
Eligibility: 4 Hours to 48 Hours
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Albany, New York

Conditions: Opioid Cessation
Interventions: Motivational Interviewing and Guided Opioid Tapering Support, Enhanced Usual Care; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Non-diabetic Chronic Kidney Disease
Interventions: Finerenone (BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 57
States / cities: Huntsville, Alabama • Chula Vista, California • El Centro, California + 49 more

Conditions: Carcinoma, Hepatocellular
Interventions: Doxorubicin 20 mg/m2, Doxorubicin 30 mg/m2, Best Standard of Care; Drug
Lead sponsor: Valerio Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 3
States / cities: Canton, Ohio • Hershey, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: oregovomab; Biological
Lead sponsor: AltaRex; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 29
States / cities: Berkeley, California • Los Angeles, California • Orange, California + 25 more

Conditions: Motor Recovery
Interventions: BreEStim, EStim; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Venous Thromboembolism
Interventions: TAK-442, Enoxaparin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,045 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 38
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 35 more

Conditions: Dry Eye Disease (DED)
Interventions: NOV03, Placebo; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 29
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Glendale, California + 25 more

Conditions: Adhesive Capsulitis
Interventions: Dynasplint, Standard of Care; Device · Other
Lead sponsor: Dynasplint Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Autism Spectrum Disorders
Interventions: Arbaclofen; Drug
Lead sponsor: Seaside Therapeutics, Inc.; Industry
Eligibility: 5 Years to 21 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 24
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 21 more

Conditions: Post-Traumatic Stress Disorder, Mental Disorders, Depression
Interventions: Trauma Recovery and Empowerment Model (TREM), Usual care; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 20 Years to 60 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 61
States / cities: Little Rock, Arkansas • Carson, California • Cerritos, California + 58 more

Conditions: Chemotherapy-Associated Paronychia
Interventions: VBP-926; Drug
Lead sponsor: Veloce BioPharma LLC; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 8
States / cities: Fountain Valley, California • Chicago, Illinois • St Louis, Missouri + 5 more

Conditions: Glioblastoma
Interventions: Trans Sodium Crocetinate plus SOC, Standard of Care (SOC); Drug · Other
Lead sponsor: Diffusion Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Irvine, California • Redwood City, California • Santa Monica, California + 10 more

Search by objective public record fields.

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

VerTouch Device: A Prospective Randomized Controlled Trial

Study of Evobrutinib in Participants With RMS

Acamprosate: Genes Associated With Response

Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007

Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa

Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis

Randomized Controlled Trial of Surfactant Delivery Via Laryngeal Mask Airway (LMA) Versus Endotracheal Intubation

Motivational Interviewing and Guided Opioid Tapering Support to Promote Postoperative Opioid Cessation

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma

Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy

BreEStim for Motor Recovery in Chronic Stroke With Severe Impairment (Pilot)

Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement

Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

Adhesive Capsulitis and Dynamic Splinting

Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders

The Trauma Recovery and Empowerment Model for Treating Post-Traumatic Stress Disorder in Women

Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

A Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients

Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects